Bicycle Therapeutics plc

Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called 'Bicycles'—fully synthetic, short peptides constrained to form two loops. This unique structural geometry allows for high affinity and selectivity, combining the pharmacological properties of biologics with the manufacturing and pharmacokinetic advantages of small molecules. The company focuses on oncology, particularly solid tumors, and is expanding into radiopharmaceuticals. Headquartered in Cambridge, UK, with a significant operational presence in Lexington, Massachusetts, the company operates as a transatlantic entity. It is currently in a strategic transition, narrowing its pipeline to focus on next-generation therapeutics, including Bicycle Drug Conjugates (BDCs) and Bicycle Radioconjugates (BRCs), following a strategic reprioritization in early 2026.